Somatostatin-14 (reduced)
CAS: 40958-31-4
Ref. 3D-FS109331
1mg | 514,00 € | ||
2mg | 865,00 € | ||
5mg | 1.607,00 € | ||
10mg | 2.785,00 € | ||
500µg | 336,00 € |
Información del producto
- H-Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH H-AGCKNFFWKTFTSC-OH
- 12: PN: WO03062429 SEQID: 12 unclaimedsequence
- 147: PN: US20090175821SEQID: 175 claimed protein
- 1702: PN: WO03060071 SEQID: 1726 unclaimed
- 1: PN: CN1372000 PAGE: 1 claimedsequence
- 1: PN: WO2010003939 PAGE: 1 unclaimedsequence
- 1: PN: WO9966950 SEQID: 1 claimed protein
- 37: PN: WO2009150470 PAGE: 36 unclaimedsequence
- 3: PN: WO2009123735SEQID: 3 unclaimed protein
- 456: PN: US20080312157 SEQID: 504 unclaimedsequence
- Ver más sinónimos
- 61: PN: WO9966952SEQID: 58 unclaimed protein
- 64: PN: WO2008041849 SEQID: 66 claimed protein
- 7: PN: WO0075166 SEQID: 7 unclaimedsequence
- 9: PN: ES2257158 PAGE: 2 unclaimedsequence
- Dihydrosomatostatin
Somatostatin-14 (reduced) H-Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys is a synthetic peptide that is an adjuvant for vaccines. It induces a biphasic response by increasing the humoral immune response and decreasing the cellular immune response. Somatostatin has been shown to decrease the severity of symptoms in patients with psychiatric disorders and can be used as a long term treatment for these conditions. Somatostatin also has effects on the pancreas, such as inhibiting insulin release, leading to decreased blood glucose levels. Its disulfide bond in its structure may be important for its activity and stability.
Propiedades químicas
Consulta técnica sobre: 3D-FS109331 Somatostatin-14 (reduced)
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.